Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MRSA bacteraemia.

Ian M Gould1

  • 1Department of Medical Microbiology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK. i.m.gould@abdn.ac.uk

International Journal of Antimicrobial Agents
|September 19, 2007
PubMed
Summary
This summary is machine-generated.

Methicillin-resistant Staphylococcus aureus (MRSA) infections and bacteremia are increasing globally, posing a significant public health threat. New antibiotics may replace current treatments, but addressing the root causes of MRSA is crucial for pandemic control.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods for SARS-CoV-2 hospital disinfection, <i>in vitro</i> observations.

Infection prevention in practice·2024
Same author

Laboratory Surveillance, Quality Management, and Its Role in Addressing Antimicrobial Resistance in Africa: A Narrative Review.

Antibiotics (Basel, Switzerland)·2023
Same author

Chlorhexidine Resistance or Cross-Resistance, That Is the Question.

Antibiotics (Basel, Switzerland)·2023
Same author

Antimicrobial Synergy Testing: Comparing the Tobramycin and Ceftazidime Gradient Diffusion Methodology Used in Assessing Synergy in Cystic Fibrosis-Derived Multidrug-Resistant <i>Pseudomonas aeruginosa</i>.

Antibiotics (Basel, Switzerland)·2021
Same author

Trends of Antimicrobial Resistance and Combination Susceptibility Testing of Multidrug-Resistant Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients: a 10-Year Update.

Antimicrobial agents and chemotherapy·2021
Same author

Author Correction: A nonlinear time-series analysis approach to identify thresholds in associations between population antibiotic use and rates of resistance.

Nature microbiology·2020
Same journal

Lactobacillus rhamnosus-Derived Postbiotics Inhibit Proliferation, Invasion, and EMT-Associated Signaling in Colorectal Cancer Cells.

International journal of antimicrobial agents·2026
Same journal

Missed opportunities for antibiotic de-escalation among clinically stable adult patients with bloodstream infection: secondary analysis of a prospective, multicenter study.

International journal of antimicrobial agents·2026
Same journal

Genomic characterization of high-risk ST340 and ST437 Klebsiella pneumoniae co-harboring bla<sub>NDM-1</sub> and bla<sub>KPC-2</sub> from wastewater.

International journal of antimicrobial agents·2026
Same journal

Clinical Characteristics and Therapeutic Dilemmas in Nocardiosis: Insights from a Case Series.

International journal of antimicrobial agents·2026
Same journal

Mechanisms Underlying Altered Ceftazidime-Avibactam resistance in Klebsiella pneumoniae Driven by KPC-234 Mutation and IncX3-NDM-1 Plasmid Transfer.

International journal of antimicrobial agents·2026
Same journal

Clinical outcomes and nephrotoxicity of polymyxin B versus colistin in real-world practice: a systematic review and meta-analysis of observational studies.

International journal of antimicrobial agents·2026
See all related articles

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Public Health

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) has been a pandemic for over a decade.
  • MRSA causes a significant increase in serious staphylococcal infections, including bacteremia, with over 50% of cases in many countries attributed to MRSA.
  • Methicillin-susceptible S. aureus (MSSA) bacteremia may also be increasing in some regions, adding to the overall burden.

Purpose of the Study:

  • To review the current landscape of MRSA infections and their treatment.
  • To discuss the challenges associated with standard glycopeptide treatment for MRSA bacteremia.
  • To explore the potential of new antibiotics and the broader control strategies for this pandemic disease.

Main Methods:

  • Literature review of recent studies on MRSA epidemiology and treatment.

Related Experiment Videos

  • Analysis of trends in S. aureus bacteremia, distinguishing between MRSA and MSSA.
  • Evaluation of current and emerging therapeutic options for MRSA infections.

    • Main Results:

    • MRSA bacteremia is a growing global concern with significantly higher mortality compared to MSSA.
    • Standard glycopeptide treatment for MRSA bacteremia may be suboptimal due to increasing resistance, MIC drift, and toxicity concerns.
    • Newer antibiotics are emerging as potential replacements for glycopeptides as the gold standard treatment.

    Conclusions:

    • MRSA represents an additional burden of infection with higher mortality, not a replacement for MSSA.
    • Control of the MRSA pandemic requires addressing underlying causes, not just relying on new antibiotics.
    • Further research and strategic interventions are needed to effectively manage and control MRSA infections worldwide.